Validation of the HFA-ICOS risk assessment tool with real-world data from a prospective cohort of breast cancer patients in treatment with anthracyclines and trastuzumab
Event:
ESC Congress 2024
Topic:
Cardio-Oncology
Session:
Cardiomyopathy in cancer patients: prevalence, risk assessment, imaging, and prevention